Stock Information
Immunovant Inc (IMVT)
Ticker Symbol: IMVT
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $5,093.54 mil
Piotroski score: 3
PE Ratio: N/A
EPS (TTM): -2.81
Revenue (TTM): $0.00 M
Dividend Yield: N/A
ROE: -69.59%
Latest News
-
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Mon, Sep 28, 2026 8:02 AM
-
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Sun, Sep 27, 2026 2:40 PM
-
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Thu, Sep 24, 2026 3:50 PM
-
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Thu, Sep 24, 2026 2:14 PM
-
Roivant reports top-line data from IMVT-1402 CLE trial
Thu, Sep 24, 2026 9:32 AM
-
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
Wed, Sep 23, 2026 5:44 PM
-
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
Wed, Sep 23, 2026 12:32 PM
-
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
Wed, Sep 23, 2026 12:12 PM
-
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
Wed, Sep 23, 2026 12:10 PM
-
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Wed, Sep 23, 2026 11:00 AM
Key Financials
Financial data not available
